Literature DB >> 18196322

The usefulness of distal splenorenal shunt in children with portal hypertension for the treatment of severe thrombocytopenia and leukopenia.

Suk-Bae Moon1, Sung-Eun Jung, Jong-Won Ha, Kwi-Won Park, Jeong-Kee Seo, Woo-Ki Kim.   

Abstract

BACKGROUND: In the current era of transplantation and therapeutic endoscopy, the role of the distal splenorenal shunt (DSRS) for portal hypertension (PH) has diminished. We reviewed the outcome of the use of DSRS in children to determine the usefulness of this operation.
METHODS: In the follow-up course for PH from 1987 to 2006, 15 patients who developed severe thrombocytopenia (platelet count <50 x 10(3)/mm(3)) and/or leukopenia (WBC count <3000/mm(3)) with normal liver function were referred for DSRS. Primary diagnosis was portal vein thrombosis (N=10) and congenital hepatic fibrosis (N=5). Platelet, WBC count, liver function test, and spleen size were checked before and after DSRS. Shunt patency was accessed postoperatively. Operative morbidity, mortality, and long-term outcomes were measured.
RESULTS: Platelet count and WBC count increased in individual patients. Mean value of each count increased significantly after DSRS (p=0.002, .004, respectively). Spleen size decreased significantly (N=7, p=0.018). Shunt patency rate was 100%. There was one postoperative complication and no postoperative mortality. Two patients developed portopulmonary hypertension. No patients underwent subsequent transplantation or endoscopic treatment for gastroesophageal varices after DSRS.
CONCLUSIONS: DSRS is an effective and reliable procedure for children with PH and is still useful for selected pediatric patients.

Entities:  

Mesh:

Year:  2008        PMID: 18196322     DOI: 10.1007/s00268-007-9356-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Surgical guidelines for the management of extra-hepatic portal vein obstruction.

Authors:  Riccardo Superina; Benjamin Shneider; Sukru Emre; Shiv Sarin; Jean de Ville de Goyet
Journal:  Pediatr Transplant       Date:  2006-12

2.  Improved results with selective distal splenorenal shunt in a highly selected patient population. A prospective study.

Authors:  K J Paquet; M A Mercado; P Koussouris; J F Kalk; F Siemens; F Cuan-Orozco
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

3.  [Portal hypertension. Choice of therapy for children under 10 years: shunt or palliative surgery?].

Authors:  J N Le Tourneau; M Carcassonne
Journal:  Chir Pediatr       Date:  1983

4.  Distal splenorenal shunt with splenopancreatic disconnection for portal hypertension in biliary atresia.

Authors:  T Hasegawa; H Tamada; Y Fukui; H Tanano; A Okada
Journal:  Pediatr Surg Int       Date:  1999       Impact factor: 1.827

5.  Pediatric gastroesophageal varices: treatment strategy and long-term results.

Authors:  Tetsuya Mitsunaga; Hideo Yoshida; Katsunori Kouchi; Tomoro Hishiki; Takeshi Saito; Shin-ichi Yamada; Yoshiharu Sato; Keita Terui; Mitsuyuki Nakata; Ayako Takenouchi; Naomi Ohnuma
Journal:  J Pediatr Surg       Date:  2006-12       Impact factor: 2.545

6.  Selective distal splenorenal shunts for intractable variceal bleeding in pediatric portal hypertension.

Authors:  S Evans; M Stovroff; K Heiss; R Ricketts
Journal:  J Pediatr Surg       Date:  1995-08       Impact factor: 2.545

7.  Endoscopic ligation of esophageal varices for prophylaxis of first bleeding in children and adolescents with portal hypertension: preliminary results of a prospective study.

Authors:  Danuta Celińska-Cedro; Mikotaj Teisseyre; Marek Woynarowski; Piotr Socha; Jerzy Socha; Józef Ryzko
Journal:  J Pediatr Surg       Date:  2003-07       Impact factor: 2.545

8.  Portosystemic shunts in children: a 15-year experience.

Authors:  Jean F Botha; B Daniel Campos; Wendy J Grant; Simon P Horslen; Debra L Sudan; Byers W Shaw; Alan N Langnas
Journal:  J Am Coll Surg       Date:  2004-08       Impact factor: 6.113

9.  Portal obstruction in children. II. Results of surgical portosystemic shunts.

Authors:  F Alvarez; O Bernard; F Brunelle; P Hadchouel; M Odièvre; D Alagille
Journal:  J Pediatr       Date:  1983-11       Impact factor: 4.406

10.  Distal splenorenal shunts for the treatment of severe thrombocytopenia from portal hypertension in children.

Authors:  J Shilyansky; E A Roberts; R A Superina
Journal:  J Gastrointest Surg       Date:  1999 Mar-Apr       Impact factor: 3.267

View more
  7 in total

1.  Thrombocytopenia and splenomegaly: an unusual presentation of congenital hepatic fibrosis.

Authors:  Serena Botto Poala; Gianni Bisogno; Raffaella Colombatti
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

2.  Management of portal hypertension in children.

Authors:  Elizabeth Mileti; Philip Rosenthal
Journal:  Curr Gastroenterol Rep       Date:  2011-02

3.  Pathological changes in pulmonary circulation in carbon tetrachloride (CCl4)-induced cirrhotic mice.

Authors:  Mita Das; Marjan Boerma; Jessica R Goree; Elise G Lavoie; Michel Fausther; Igor B Gubrij; Amanda K Pangle; Larry G Johnson; Jonathan A Dranoff
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

Review 4.  Pediatric Vascular Surgery Review with a 30-Year-Experience in a Tertiary Referral Center.

Authors:  Seung-Kee Min; Sungsin Cho; Hyun-Young Kim; Sang Joon Kim
Journal:  Vasc Specialist Int       Date:  2017-06-30

5.  Etiology and management of hemorrhagic complications of portal hypertension in children.

Authors:  Alejandro Costaguta; Fernando Alvarez
Journal:  Int J Hepatol       Date:  2012-10-11

6.  Portal hypertension: A critical appraisal of shunt procedures with emphasis on distal splenorenal shunt in children.

Authors:  Nitin Sharma; Minu Bajpai; Arbinder Kumar; Shashi Paul; Manisha Jana
Journal:  J Indian Assoc Pediatr Surg       Date:  2014-04

7.  Transjugular intrahepatic portosystemic shunt versus surgical shunting in the management of portal hypertension.

Authors:  Long Huang; Qing-Sheng Yu; Qi Zhang; Ju-Da Liu; Zhen Wang
Journal:  Chin Med J (Engl)       Date:  2015-03-20       Impact factor: 2.628

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.